|
US2015352090A1
|
|
Carbamate derivatives
|
|
US2015335596A1
|
|
1-(2-fluorobiphenyl-4-yl)-cyclopropanecarboxylic acid derivatives for the treatment of down's syndrome
|
|
WO2015173133A1
|
|
Formulations and methods of treating alzheimer's disease and other proteinopathies by combination therapy
|
|
US2015158858A1
|
|
Heteroaryl derivatives
|
|
TW201609206A
|
|
Improved method and system for the administration of a pulmonary surfactant by atomization
|
|
CA2917752A1
|
|
Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation
|
|
KR20160021772A
|
|
Improved process for the preparation of derivatives of 1-(2-fluoro[1,1′-biphenyl]-4-yl)-cyclopropanecarboxylic acid
|
|
US2014364412A1
|
|
Kinase inhibitors
|
|
WO2015185128A1
|
|
3,5-dichloro,4-(3,4-(cyclo-)alkoxyphenyl)- 2-carbonyloxy)ethyl)pyridine derivatives as pde-4 inhibitors
|
|
US2014322142A1
|
|
Particle size reduction of an antimuscarinic compound
|
|
CN104854105A
|
|
Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
|
|
KR20150092173A
|
|
Phenylethylpyridine derivatives as pde4-inhibitors
|
|
WO2014086855A1
|
|
Phenylethylpyridine derivatives as pde4-inhibitors
|
|
CN104812771A
|
|
Reconstituted pulmonary surfactants
|
|
US2014158126A1
|
|
Drug delivery device for the treatment of patients with respiratory diseases
|
|
TN2013000429A1
|
|
Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
|
|
CA2825821A1
|
|
1-phenylalkanecarboxylic acid derivatives for the treatment of alzheimer's disease and multiple sclerosis
|
|
CA2883749A1
|
|
Aerosol inhalation device
|
|
US2014069419A1
|
|
Isoxazolidine derivatives
|
|
CA2914457A1
|
|
Kinase inhibitors
|
